Evidence map›Paper›PMID 39289471›Full record

Trial reportScientific reports2024

Resistance exercise in early-stage ALS patients, ALSFRS-R, Sickness Impact Profile ALS-19, and muscle transcriptome: a pilot study.

Omar Jawdat, Jason Rucker, Tomoki Nakano, Kotaro Takeno, Jeffery Statland, Mamatha Pasnoor, Mazen M Dimachkie, Carla Sabus, Yomna Badawi, Suzanne L Hunt and 7 more

Registry-linked trialAbstract readClinical Trial
In one paragraph

Trial report in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03201991 (ALS Study Determining Various Biomarkers and Strength Comparison After Exercise), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03201991 nacompletednot on this map

ALS Study Determining Various Biomarkers and Strength Comparison After Exercise

TypeinterventionalSponsorUniversity of Kansas Medical CenterRan2017 to 2018Enrolled9ConditionsAmyotrophic Lateral SclerosisArmsResistance Exercise Program
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. A blood based mitochondrial functional index biomarker for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  3. Review
  4. The Neuromuscular Junction: A Shared Vulnerability in Aging and Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Omar JawdatDepartment of Neurology, University of Kansas Medical Center, Kansas City, USA.
Jason RuckerDepartment of Physical Therapy, Rehabilitation Science, and Athletic Training, University of Kansas Medical Center, Kansas City, USA.
Tomoki NakanoLaboratory of Neurobiology of Aging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakaecho, Itabashi-ku, Tokyo, 173-0015, Japan.
Kotaro TakenoLaboratory of Neurobiology of Aging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakaecho, Itabashi-ku, Tokyo, 173-0015, Japan.
Jeffery StatlandDepartment of Neurology, University of Kansas Medical Center, Kansas City, USA.
Mamatha PasnoorDepartment of Neurology, University of Kansas Medical Center, Kansas City, USA.
Mazen M DimachkieDepartment of Neurology, University of Kansas Medical Center, Kansas City, USA.
Carla SabusDepartment of Physical Therapy, Rehabilitation Science, and Athletic Training, University of Kansas Medical Center, Kansas City, USA.
Yomna BadawiDepartment of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, USA.
Suzanne L HuntDepartment of Neurology, University of Kansas Medical Center, Kansas City, USA.
Naoko H TomiokaLaboratory of Neurobiology of Aging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakaecho, Itabashi-ku, Tokyo, 173-0015, Japan.
Sumedha GunewardenaDepartment of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, USA.
Clark BloomerGenome Sequencing Facility, University of Kansas Medical Center, Kansas City, USA.
Heather M WilkinsDepartment of Neurology, University of Kansas Medical Center, Kansas City, USA.
Laura HerbelinDepartment of Neurology, University of Kansas Medical Center, Kansas City, USA.
Richard J BarohnDepartment of Neurology, University of Kansas Medical Center, Kansas City, USA. rbarohn@health.missouri.edu.
Hiroshi NishimuneLaboratory of Neurobiology of Aging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakaecho, Itabashi-ku, Tokyo, 173-0015, Japan. HiroshiNishimune@gmail.com.

Funding

RADx-UP: Improving the Response of Local Urban and Rural Communities to Disparities in Covid-19 TestingUL1TR002366 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Mario Castro, JAMES STEVEN LEEDER · 2017 to 2026
$44.3M
University of Kansas Alzheimer's Disease Core CentersP30AG035982 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI MAHNKEN, JONATHAN D · 2011 to 2020
$16.6M
Using PCORnet to Expand the DS-CONNECT Cohort Through Healthcare System Recruitment, Incorporating Electronic Health Records, and Assessing Self-DeterminationU54HD090216 · NICHD · UNIVERSITY OF KANSAS LAWRENCE · PI COLOMBO, JOHN A. · 2016 to 2020
$6.2M
Molecular Regulation of Cell Development and Differentiation Phase III COBREP30GM122731 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI LITTLE, CHARLES D. · 2017 to 2021
$5.6M
Active zone loss cause dying back neuropathy in amyotrophic lateral sclerosisR01NS078214 · NINDS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NISHIMUNE, HIROSHI · 2012 to 2016
$1.6M
High Throughput Sequencing System for KUMC Genomics CoreS10OD021743 · OD · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SMITH, PETER G · 2017 to 2017
$493k
Japan Society for the Promotion of Science 19K24690NCATS NIH HHS UL1 TR002366NIA NIH HHS P30 AG035982NICHD NIH HHS U54 HD090216NIGMS NIH HHS P30 GM122731NIH HHS S10 OD021743NINDS NIH HHS R01 NS078214NINDS NIH HHS R01NS078214
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) patients lack effective treatments to maintain motor and neuromuscular function. This study aimed to evaluate the effect of a home-based exercise program on muscle strength, ALS scores, and transcriptome in ALS patients, Clinical Trials.gov #NCT03201991 (28/06/2017). An open-label, non-randomized pilot clinical trial was conducted in seven individuals with early-stage ALS. Participants were given 3 months of home-based resistance exercise focusing on the quadriceps muscles. The strength of exercised muscle was evaluated using bilateral quadriceps strength with manual muscle testing, handheld dynamometers, five times sit-to-stand, and Timed-Up-and-Go before and after the exercise program. In addition, changes in the Sickness Impact Profile ALS-19 (SIP/ALS-19) as the functional outcome measure and the transcriptome of exercised muscles were compared before and after the exercise. The primary outcome of muscle strength did not change significantly by the exercise program. The exercise program maintained the SIP/ALS-19 and the ALS Functional Rating Scale-Revised (ALSFRS-R). Transcriptome analysis revealed that exercise reverted the expression level of genes decreased in ALS, including parvalbumin. Three months of moderately intense strength and conditioning exercise maintained muscle strength of the exercised muscle and ALSFRS-R scores and had a positive effect on patients' muscle transcriptome.

Indexed as

Amyotrophic Lateral SclerosisMuscle StrengthResistance TrainingTranscriptomeAdultAgedFemaleHumansMaleMiddle AgedMuscle, SkeletalPilot ProjectsQuadriceps MuscleAmyotrophic lateral sclerosisClinical trialExercise

Identifiers

PMID39289471
PMCPMC11408620

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.